EXTON, Pa. — Drug maker ViroPharma has launched an education campaign focused on a rare, debilitating and life-threatening genetic disorder.
The company announced Wednesday the launch of the unbranded campaign focused on hereditary angioedema, particularly the emotional and psychological burden faced by patients with the disease, which results from deficiency of the human plasma protein C1 inhibitor and causes attacks of swelling and pain.
